Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma (Q34243444)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

single-nucleotide polymorphism

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

1

object named as

Robert J Motzer

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Thomas E Hutson

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Gary R Hudes

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Robert A Figlin

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jean-Francois Martini

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Patricia A English

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Xin Huang

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Olga Valota

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

J Andrew Williams

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

7 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

74

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

739-750

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

copyright license

Creative Commons Attribution 4.0 International

7 August 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

Aptamer-based multiplexed proteomic technology for biomarker discovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

Modes of resistance to anti-angiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

6 July 2018

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2539-0

21 January 2018

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2539-0

21 January 2018

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2539-0

21 January 2018

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2539-0

21 January 2018

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2539-0

21 January 2018

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2539-0

21 January 2018

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175044

28 October 2018

‘Fit-for-purpose’ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2539-0

21 January 2018

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25100134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25100134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive factors for response to treatment in patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25100134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25100134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25100134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25100134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-014-2539-0

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34243444&oldid=2196413197"